ReviewCurrent pharmaceutical design2025
Nano Selenium: A Promising Solution for Infectious Diseases - Current Status and Future Prospects.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Editorial: ADME of drugs to treat infectious diseases.Frontiers in pharmacology · 2026Article
- Selenium Compounds and Their Bioactivities: Molecular Mechanisms and Prospects for Functional Food and Therapeutic Applications.Plants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to increasing antibiotic resistance, researchers are investigating the medicinal potential of nanoparticles, particularly their antibacterial and antiviral properties. Among other things, this concern mandates the journey for novel and more potent antibacterial drugs. The crucial role of nanoparticles in the treatment of various microbial diseases has been demonstrated in several research studies. AIM &
objectiveThis study focuses on the role of Selenium nanoparticles (SeNPs) against infectious diseases, with an emphasis on exploring their probable mechanisms of action. METHODOLOGY: Nanoparticles have been exploited as delivery mechanisms and broad-spectrum inhibitors in viral and microbial studies. Their significant therapeutic potential stems from their high surface area to volume ratio, which enables diverse applications. Various materials have been employed in the synthesis of nanoparticles, each tailored to meet specific therapeutic requirements. The unique combination of biological relevance, environmental friendliness, and versatile applications makes SeNPs a promising alternative to other nanoparticles in various fields.
resultsThe therapeutic potential of nanoparticles, especially Selenium nanoparticles (SeNPs), is significant and warrants further exploration. They have shown promise as delivery agents and potent materials for combating infectious diseases, making them a valuable asset in the fight against antibiotic resistance.
conclusionSelenium nanoparticles (SeNPs) are potential biological prospects because of their biocompatibility, bioavailability, and low toxicity. Size, shape, and synthesis affect SeNP uses in biological systems. SeNPs are chemopreventive, anti-inflammatory, and antioxidant medicines that may cure fungal, bacterial, and parasite infections, cancer, and diabetes. They have better absorption, bioavailability, and antibacterial action than micron-size particles. Their large surface area facilitates biological contact and bioactive chemical functionalization. Functionalized SeNPs are less cytotoxic than other seleniums. They prevent DNA oxidation, detoxify heavy metals, and inhibit hydroxyl radicals. In conclusion, selenium nanoparticles have considerable promise for medication delivery, antimicrobials, and cancer and diabetes treatment. They are attractive nanomedicine prospects due to their low toxicity, biocompatibility, and high bioavailability.
Indexed as
Identifiers
40289975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.